Back to Search
ELLEN KEMPER, M.D.
M.D.
Family Medicine Physician
NPI: 1457337115Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
M5212(ID)5943(AK)
Research & Publications (20)
Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
PMID 17554106·J Clin Pharmacol·2007
3-trial
[Severe phenytoin intoxication in patients with hypoalbuminaemia].
PMID 17315493·Ned Tijdschr Geneeskd·2007
5-case
Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
PMID 17244765·J Clin Pharmacol·2007
2-rct
Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
PMID 17192761·CNS Spectr·2007
2-rct
Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
PMID 17715422·J Clin Pharmacol·2007
4-observational
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
PMID 17027258·Eur J Cancer·2006
7-preclinical
Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
PMID 16855078·J Clin Pharmacol·2006
3-trial
Validity and reliability of the audit and CAGE-AID in Northern Plains American Indians.
PMID 16279320·Psychol Rep·2005
8-other
A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.
PMID 15578748·J Mass Spectrom·2004
7-preclinical
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
PMID 15245774·Cancer Treat Rev·2004
6-review
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
PMID 14605863·Cancer Chemother Pharmacol·2004
7-preclinical
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
PMID 15110893·Eur J Cancer·2004
7-preclinical
Evaluation of monocot and eudicot divergence using the sugarcane transcriptome.
PMID 15020759·Plant Physiol·2004
4-observational
Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.
PMID 14654039·Anal Biochem·2004
8-other
Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.
PMID 14630360·J Chromatogr B Analyt Technol Biomed Life Sci·2003
7-preclinical
Analysis and functional annotation of an expressed sequence tag collection for tropical crop sugarcane.
PMID 14613979·Genome Res·2003
8-other
Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus.
PMID 14563026·Psychol Rep·2003
4-observational
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
PMID 12855665·Clin Cancer Res·2003
7-preclinical
Tyramine pharmacokinetics and reduced bioavailability with food.
PMID 12817523·J Clin Pharmacol·2003
3-trial
Fastidian gum: the Xylella fastidiosa exopolysaccharide possibly involved in bacterial pathogenicity.
PMID 11583843·FEMS Microbiol Lett·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7300 KLAWOCK-HOLLIS HIGHWAY
KLAWOCK, AK 99925 - Phone
- (907) 755-4800
Quick Facts
- NPI
- 1457337115
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile